Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Accenture
Chinese Patent Office
Citi
Argus Health
Fuji
QuintilesIMS
Teva
Baxter

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,642,608

« Back to Dashboard

Summary for Patent: 8,642,608
Title:Quinazoline derivatives as VEGF inhibitors
Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from one of the following three groups: 1) C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. ##STR00001##
Inventor(s): Thomas; Andrew Peter (Macclesfield, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield, GB), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:12/761,105
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,642,608

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,642,608

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99402759Nov 5, 1999
99402877Nov 19, 1999

International Patents Family Members for US Patent 8,642,608

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway 20022139 ➤ Subscribe
Mexico PA02004366 ➤ Subscribe
South Korea 100881105 ➤ Subscribe
Luxembourg 92057 ➤ Subscribe
South Korea 20080023270 ➤ Subscribe
South Korea 100881104 ➤ Subscribe
South Korea 20070104683 ➤ Subscribe
Japan 3522727 ➤ Subscribe
Japan 2003513089 ➤ Subscribe
Iceland 6335 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Accenture
Moodys
UBS
Teva
US Department of Justice
Cerilliant
Johnson and Johnson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot